LLY Company Profile and Key Details

Q: Who are the executives of LLY?

Mr. Jacob S. Van NaardenSenior Vice President, Chief Executive Officer of Loxo Oncology & Pres of Lilly OncologyMr. Donald A. ZakrowskiChief Accounting Officer & Vice President of Fin.Ms. Leigh Ann PuseyExecutive Vice President of Corporation Affairs & CommunicationsMr. Alonzo WeemsEVice President of Enterprise Risk Management and Chief Ethics & Compliance OfficerMr. Patrik JonssonEVice President, Chief Customer Officer, Pres of Lilly USA & Lilly ImmunologyMr. Eric DozierExecutive Vice President of HR & DiversityDr. Daniel M. Skovronsky M.D., Ph.D.Executive Vice President, Chief Scientific & Medical Officer and Pres of Lilly Research LaboratoriesMr. Martin Bott MIBSVice President of Fin. & Special ProjectsMr. Diogo RauEVice President & Chief Information and Digital OfficerMs. Anat AshkenaziExecutive Vice President & Chief Financial OfficerMs. Anat Hakim J.D.Executive Vice President, Gen. Counsel & Sec.Mr. David A. RicksChairman, Chief Executive Officer & Pres

NYSE : LLY

Eli Lilly and

$935.62

-18.9-1.98%

At Close 4:00 PM

70.76

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Eli Lilly and Company (LLY) stock declined over -1.98%, trading at $935.62 on NYSE, down from the previous close of $954.52. The stock opened at $945.75, fluctuating between $930.02 and $957.69 in the recent session.

Stock Snapshot

954.52

Prev. Close

883.99B

Market Cap

930.02

Day Low

40.7

P/E Ratio

22.99

EPS (TTM)

-3.32

Cash Flow per Share

945.75

Open

944.82M

Number of Shares

957.6875

Day High

99.56%

Free Float in %

11.35

Book Value

2.19M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2026	945.00	957.69	930.02	935.58	2.73M
Apr 01, 2026	926.88	976.68	925.99	954.52	6.27M
Mar 31, 2026	893.49	924.14	892.14	919.77	3.41M
Mar 30, 2026	888.48	897.43	883.11	886.63	3.07M
Mar 27, 2026	896.00	900.83	877.11	878.24	2.73M
Mar 25, 2026	912.49	922.15	909.09	916.31	2.17M
Mar 24, 2026	907.00	908.67	895.61	903.02	2.57M
Mar 23, 2026	913.49	926.78	907.23	910.55	2.81M
Mar 20, 2026	910.55	925.38	899.29	906.70	4.82M
Mar 19, 2026	914.00	924.53	910.86	917.50	2.36M
Mar 18, 2026	925.00	929.00	905.11	918.05	3.44M
Mar 17, 2026	978.92	981.17	925.25	930.35	5.63M
Mar 16, 2026	991.98	998.17	975.51	989.12	2.28M
Mar 13, 2026	980.13	1,003.22	978.00	985.08	1.98M
Mar 12, 2026	993.45	994.50	973.16	977.25	2.33M
Mar 11, 2026	1,000.03	1,002.93	990.30	999.84	1.43M
Mar 10, 2026	1,006.00	1,012.00	994.00	1,001.35	1.66M
Mar 09, 2026	986.89	1,008.93	980.58	1,008.39	2.8M
Mar 06, 2026	975.00	991.22	966.09	990.33	2.62M
Mar 03, 2026	1,015.00	1,020.01	995.07	1,007.73	2.82M

Contact Details

Indianapolis, IN 46285

United States

https://www.lilly.com 317 276 2000

About Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Stock Peers

JNJ

-1.08-0.44%

Johnson & Johnson$243.04 ABBV

-6.185-2.88%

AbbVie Inc.$208.80 AZN

2.76+1.37%

AstraZeneca PLC$203.49 NVS

-1.05-0.68%

Novartis AG$154.03 MRK

0.03+0.02%

Merck & Co., Inc.$120.87 BMY

-2.13-3.45%

Bristol-Myers Squibb Company$59.60 GSK

0.7+1.25%

GSK plc$56.69 NVO

0.495+1.36%

Novo Nordisk A/S$36.98 PFE

-0.22-0.77%

Pfizer Inc.$28.33 OGN

0.22+3.58%

Organon & Co.$6.36

Company Overview

Eli Lilly and Company (NYSE:LLY) closed at $935.62 USD, losing -$18.90 (-1.98%) from the previous close of $954.52. The stock is currently mid-range between its 52-week high and low $623.78 and $1.13 thousand. With a market capitalization of about $883.99 billion, Eli Lilly and Company is classified as a mega-cap and shows lower-than-market volatility (beta ~0.50). Key stats such as the average daily volume over the past year has been around 3.24 million shares, volume is running light vs its 52-week average. Headquartered in Indianapolis, IN, Eli Lilly and Company operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO David A. Ricks, the company employs approximately 47,000 people and listed since June 01, 1972. Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -1.25%, SMA50 -2.97%, SMA200 17.08%). The stock’s 14-day RSI is 46.82 (neutral), while the ATR of 35.82 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -9.87% below its high and over 63.84% above its low. Average 10-day trading volume of 3.28 million shares is in line with the 3-month average of 3.24 million, indicating normal recent market interest.

Valuation Metrics

Eli Lilly and Company trades at a P/E ratio of 40.71, slightly above the S&P 500 average, with a price-to-sales ratio of 13.56 and a price-to-book ratio of 31.66 reflecting a rich premium to book value. The P/FCF stands at 98.53, also above market averages. Compared to sector medians, Eli Lilly and Company P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Eli Lilly and Company last paid a dividend of 6.23 per share, this equals a trailing yield of roughly 0.55%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $979.35. This means the shares are trading near this model’s fair value.

Earnings & Analyst Outlook

Eli Lilly and Company generated EPS of $22.59 over the past year. Five-year average earnings growth is 27.59%. Wall Street analysts project EPS growth of 26.77% annually over the next five years. The latest quarter delivered EPS of $7.02. The next quarter is forecast at $7.21. Next year's EPS is expected at $86.83. Analyst sentiment is bullish. Analyst rating data shows there are 20 Strong Buy ratings, 18 Buy ratings, 3 Hold ratings, 1 Sell rating and 0 Strong Sell ratings. Price targets range from $1.50 thousand to $1.25. The high target offers 60.32% upside. The low target suggests -99.87% downside. The mean target is $1.04 thousand. This offers 11.14% upside. Eli Lilly and Company earnings surprise history is a consistent trend of beating forecasts. The quarter that ended October 30, 2025, missed forecasts by 23.37%. The prior quarter beat by 12.68%. Over the last six quarters, Apple has recorded several small beats. These include 43.07% in August 08, 2024.

Shareholding & Insider Activity

Eli Lilly and Company has 896.46 million shares outstanding. The public float is 895.44 million shares, elevated short interest at 0.90% of float. This equals 7.17 million shares. The short ratio is 2.2 days. Institutional investors hold 84.0% of the float. Insiders own 0.16%. LILLY ENDOWMENT INC holds 91.90 million shares, Ricks David A has 546.60 thousand shares and Skovronsky Daniel has 137.66 thousand shares. Over the past six months, insider transactions show net selling. They sold 76.13 thousand shares across 28 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Eli Lilly and generated $34.12B in revenue, or $37.78 per share. Gross margin was 80.73%, operating margin 30.26%, and net profit margin 15.36%. Returns are healthy, with ROA at 8.19% and ROE at 48.65%.
On valuation metrics, Eli Lilly and trades at a P/E of 40.71, P/S of 13.56 and P/B of 31.66. The current ratio is 1.58 and quick ratio is 1.19. Operationally, the company’s inventory turnover is 0.77 and cash conversion cycle is 401.89 days. Debt-to-equity is 1.60, supported by a cash flow-to-debt ratio of 0.40.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Eli Lilly and posted revenue of $34.12B, down slightly from $28.54B in the prior quarter. Gross profit was $27.55B (margin 80.73%). Operating income was $10.33B (margin 30.3%). Net income was$5.24B (EPS $5.82).
The company ended the quarter with $2.93B in cash and short-term investments, a total debt of $25.23B, and net debt of $22.41B. Total assets were $64.01B, with equity of $10.86B. Financials further reflected stability, with operating cash flow of $4.24B, free cash flow of - $3.15B, and capital expenditures of - $7.39B.

Price Forecast & Outlook

Our AI price prediction model suggests that Eli Lilly and Company stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.24%, with price expected at $867.86 by April 16, 2026, within a range of $846.45 to $889.01 3-Month Outlook: Projected fall of -14.65%, reaching $798.54 by July 01, 2026, with a range of $713.03 to $850.40. 1-Year Outlook: Projected gain of 19.1%, with price at $1.11 thousand by April 02, 2027, within a range of $1.07 thousand to $1.15 thousand.

Key Takeaways

Eli Lilly and Company (NYSE:LLY) shares are flat -3.11% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Eli Lilly and Company trading at a premium to the broader market with a P/E of 40.71. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $731.10, suggesting -21.86% downside. Our AI forecast model points to short-term weakness (-7.24% over two weeks), a medium-term fall (-14.65% over three months), and a longer-term gain (19.1% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Eli Lilly and Company (LLY) stock price?

Eli Lilly and Company (NYSE: LLY) stock price is $935.62 in the last trading session. During the trading session, LLY stock reached the peak price of $957.69 while $930.02 was the lowest point it dropped to. The percentage change in LLY stock occurred in the recent session was -1.98% while the dollar amount for the price change in LLY stock was - $18.90.

LLY's industry and sector of operation?

The NYSE listed LLY is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector. Eli Lilly and Company designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of LLY?

Mr. Jacob S. Van Naarden
Senior Vice President, Chief Executive Officer of Loxo Oncology & Pres of Lilly Oncology
Mr. Donald A. Zakrowski
Chief Accounting Officer & Vice President of Fin.
Ms. Leigh Ann Pusey
Executive Vice President of Corporation Affairs & Communications
Mr. Alonzo Weems
EVice President of Enterprise Risk Management and Chief Ethics & Compliance Officer
Mr. Patrik Jonsson
EVice President, Chief Customer Officer, Pres of Lilly USA & Lilly Immunology
Mr. Eric Dozier
Executive Vice President of HR & Diversity
Dr. Daniel M. Skovronsky M.D., Ph.D.
Executive Vice President, Chief Scientific & Medical Officer and Pres of Lilly Research Laboratories
Mr. Martin Bott MIBS
Vice President of Fin. & Special Projects
Mr. Diogo Rau
EVice President & Chief Information and Digital Officer
Ms. Anat Ashkenazi
Executive Vice President & Chief Financial Officer
Ms. Anat Hakim J.D.
Executive Vice President, Gen. Counsel & Sec.
Mr. David A. Ricks
Chairman, Chief Executive Officer & Pres

How LLY did perform over past 52-week?

LLY's closing price is 49.99% higher than its 52-week low of $623.78 where as its distance from 52-week high of $1,133.95 is -17.49%.

How many employees does LLY have?

Number of LLY employees currently stands at 47,000.

Link for LLY official website?

Official Website of LLY is: https://www.lilly.com

How do I contact LLY?

LLY could be contacted at phone 317 276 2000 and can also be accessed through its website. LLY operates from Lilly Corporate Center, Indianapolis, IN 46285, United States.

How many shares of LLY are traded daily?

LLY stock volume for the day was 2.19M shares. The average number of LLY shares traded daily for last 3 months was 3.24M.

What is the market cap of LLY currently?

The market value of LLY currently stands at $883.99B with its latest stock price at $935.62 and 944.82M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	47000
Beta	0.43
Sales or Revenue	$34.12B
5Y Sales Change%	0.806%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - General

LLY Company Profile and Key Details

Eli Lilly and

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Shareholding & Insider Activity

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Key Takeaways

Price Forecast & Outlook

Financial & Profitability Overview

Quarterly Financial Highlights